Results 231 to 240 of about 31,440 (256)

Coprescribing GLP-1 Receptor Agonists and Lifestyle

JAMA Internal Medicine
Michelle S, Rockwell, Elizabeth A, Polk, Camille, Mittendorf   +2 more
openaire   +2 more sources

The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review

Diabetes/Metabolism Research and Reviews, 2011
Vanita R Aroda, Robert Ratner
exaly  

Tolerance develops toward GLP-1 receptor agonists’ glucose-lowering effect in mice

European Journal of Pharmacology, 2020
Kertu Rünkorg, Eero Vasar, Vallo Volke   +2 more
exaly  

Cardiovascular safety and benefits of GLP-1 receptor agonists

Expert Opinion on Drug Safety, 2017
Andreas Brønden, Tina VILSBØLL, Filip K Knop   +2 more
exaly  

Side effects of GLP-1 receptor agonists

BMJ
Jennifer, Manne-Goehler, Juan, Franco
openaire   +2 more sources

A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment

Expert Opinion on Drug Safety, 2018
Agostino Consoli, Gloria Formoso, Maria Pompea Antonia Baldassarre   +2 more
exaly  

The promise and hope of GLP-1 receptor agonists

The Lancet Diabetes & Endocrinology
Priya, Sumithran, Jamy, Ard
openaire   +2 more sources

The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

Diabetes, Obesity and Metabolism, 2014
Baptist Gallwitz
exaly  

Treatment with GLP-1 Receptor Agonists

2018
Madsbad, Sten, Holst, Jens J.
openaire   +2 more sources

Physician perceptions of GLP-1 receptor agonists in the UK

Current Medical Research and Opinion, 2016
Louis S Matza
exaly